Simvastatin improves final visual outcome in acute optic neuritis: a randomized study

Abstract

Background: In recent years, small-scale clinical trials have indicated that statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors exert pleiotropic immunomodulatory effects, with potential therapeutic implications in multiple sclerosis (MS).

Objective: To investigate whether simvastatin treatment (80 mg daily for 6 months) in patients with optic neuritis (ON) had a beneficial effect on visual outcome and on brain MRI.

Methods: Sixty-four patients with acute ON were randomized to simvastatin treatment (n = 32) or placebo (n = 32) for 6 months. None of the patients had been on immunosuppressive therapy for 6 months prior to inclusion or treated with steroids from symptom onset. Contrast sensitivity (Arden plates), visual acuity, colour perception, visual evoked potentials (VEP) – latency and amplitude, Visual Analogue Scale (VAS) score, and gadolinium enhancing and T2 lesions on brain MRI were evaluated at screening visit, day 14 (except brain MRI), day 90 and day 180.

Results: Simvastatin had a beneficial effect on VEP in both latency (p = 0.01) and amplitude (p = 0.01), a borderline effect on the Arden score (p = 0.06) and VAS (p = 0.04), and no effect on brain MRI or on relapse rate between the groups.

Conclusion: This study provides Class I evidence that simvastatin 80 mg daily is well tolerated and possibly effective in patients with acute ON.

Keywords

disease modifying therapies multiple sclerosis

Get full access to this article

View all access options for this article.

References

Frohman

Zee

McColl

Galetta

. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4: 111–121.

The Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997; 49: 1404–1413.

Germann

Baumann

Hamzavi

. Ophthalmic diagnoses in the ED: Optic neuritis. Am J Emerg Med 2007; 25: 834–837.

Hickman

Dalton

Miller

Plant

. Management of acute optic neuritis. Lancet 2002; 360: 1953–1962.

Cucchiara

Kasner

. Use of statins in CNS disorders. J Neurol Sci 2001; 187: 81–89.

Neuhaus

Strasser-Fuchs

Fazekas

. Statins as immunomodulators: Comparison with interferon-beta 1b in MS. Neurology 2002; 59: 990–997.

Neuhaus

Stuve

Zamvil

Hartung

. Are statins a treatment option for multiple sclerosis? Lancet Neurol 2004; 3: 369–371.

Sena

Pedrosa

Graca

. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 2003; 250: 754–755.

Stuve

Prod’homme

Youssef

. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4: 237–244.

10.

Vollmer

Key

Durkalski

. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607–1608.

11.

Paraskevas

Tzovaras

Briana

Mikhailidis

. Emerging indications for statins: A pluripotent family of agents with several potential applications. Curr Pharm Des 2007; 13: 3622–3636.

12.

Aktas

Waiczies

Smorodchenko

. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725–733.

13.

Weber

Steinman

Zamvil

. Statins–treatment option for central nervous system autoimmune disease? Neurotherapeutics 2007; 4: 693–700.

14.

Kurtzke

. Clinical definition for multiple sclerosis treatment trials. Ann Neurol 1994; 36(1): S73–S79.

15.

Lanthony

. The desaturated panel D-15. Doc Ophthalmol 1978; 46: 185–189.

16.

Mäntyjärvi

. Velhagen Pfügertrident pseudoisochromatic plates in screening congenital red-green vision defects. Graefes Arch Clin Exp Ophthalmol 1991; 229: 145–146.

17.

Halliday

. Visual evoked potentials. Bull Soc Belge Ophtalmol 1983; 208: 323–331.

18.

Davidson

. Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust. Drugs 2001; 61: 197–206.

19.

Illingworth

Crouse

III Hunninghake

. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001; 17: 43–50.

20.

Sellebjerg

Nielsen

Frederiksen

Olesen

. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479–1484.

21.

Roed

Langkilde

Sellebjerg

. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804–810.

22.

Beck

Cleary

Anderson

Jr . A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581–588.

23.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

24.

Jones

Brusa

. Neurophysiological evidence for long-term repair of MS lesions: Implications for axon protection. J Neurol Sci 2003; 206: 193–198.

25.

Halliday

. Visual evoked potentials in demyelinating disease. Adv Neurol 1981; 31: 201–215.

26.

Frederiksen

Petrera

Larsson

Stigsby

Olesen

Serial

MRI

. VEP, SEP and biotesiometry in acute optic neuritis: Value of baseline results to predict the development of new lesions at one year follow up. Acta Neurol Scand 1996; 93: 246–252.

27.

Frederiksen

Sorensen

Sellebjerg

. Residual symptoms and signs after untreated acute optic neuritis. A one-year follow-up. Acta Ophthalmol Scand 1997; 75: 544–547.

28.

Frederiksen

Petrera

. Serial visual evoked potentials in 90 untreated patients with acute optic neuritis. Surv Ophthalmol 1999; 44(1): S54–S62.

29.

Trobe

Beck

Moke

Cleary

. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol 1996; 121: 547–553.

30.

Noseworthy

O’Brien

Petterson

. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514–1522.

31.

Brusaferri

Candelise

. Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435–442.

32.

Sellebjerg

Nielsen

Frederiksen

Olesen

. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479–1484.

33.

Salvatore

Morra

Orefice

. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2009 Sep 29; 73(13): 1078–1079.

34.

May

Thomas S.

Laurie Barclay

. Simvastatin Does Not Antagonize Interferon-Beta, Interim Analysis Suggests. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis: Parallel Session 7 (85). Presented October 13, 2007.

35.

Togha

Karvigh

Nabavi

. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: A double-blind randomized controlled trial. Mult Scler 2010; 16: 848–854.

36.

Aktas

Waiczies

Smorodchenko

. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725–733.

37.

Stanislaus

Pahan

Singh

. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 1999; 269: 71–74.

38.

Youssef

Stuve

Patarroyo

. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78–84.

39.

Paintlia

Singh

. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 2004; 77: 63–81.

40.

Wattjes

Harzheim

Kuhl

. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006; 27: 1794–1798.